Suitable for use to measure free Panitumumab in patient samples.
Recommended antibody pair for pharmacokinetic (PK) bridging assay to measure free drug: CABT-ZB230 - CABT-ZB231
Recommended Working Concentration: 0.005-1 μg/ml
Summary
Specifications
Antibody Isotype
IgG1, κ
Clone
3F8
Immunogen
Panitumumab
Conjugate
Unconjugated
Applications
Application Notes
Suitable for use in PK bridging ELISA. We recommend the following for sandwich ELISA (Capture - Detection): CABT-ZB230 - CABT-ZB231 Recommended Working Concentration: 0.005-1 μg/ml
General Notes
We recommend the following antibody pair to develop a pharmacokinetic (PK) bridging assay to measure free drug: CABT-ZB230 - CABT-ZB231 CABT-ZB231 is recommended for use as a detection antibody when paired with CABT-ZB230 as a capture antibody. Panitumumab with trade name Vectibix, is an FDA-approved drug for the treatment of patients with EGFR-expressing metastatic colorectal carcinoma with non-mutated (wild-type) KRAS after failure of fluoropyrimidine-, oxaliplatin- and irinotecan-containing chemotherapy regimens. It is a human monoclonal antibody. Panitumumab binds to the human EGF receptor (EGFR), preventing binding of activating ligands, such as the EGF and transforming growth factor-α.
Target
Alternative Names
Mouse monoclonal antibody to Panitumumab/Vectibix; Abenix; ABX-EGF; NSC 742319; Panitumumab
Citations
Publication ()
Have you cited CABT-ZB231 in a publication? Let us know and earn a reward for your research.
My Review for Mouse Anti-Panitumumab monoclonal antibody, clone 3F8
Creative Diagnostics products are for RESEARCH USE ONLY, please make sure your review is research based.
Required fields are marked with *
Terms and conditions:
We will select high-quality review customers and offer a $30 coupon for your next purchase.
All product reviews must be submitted in the English language.
Creative Diagnostics will not share any personal information of applicants, and all information will be treated with strict confidentiality and will not be sold or disclosed to a third party.
COA
Publication 
Loading ......
